GDx Staging System is successful in RNFL damage classification

Article

The GDx Staging System is an efficient way to interpret retinal fibre layer (RNFL) damage.

The GDx Staging System is an efficient way to interpret retinal fibre layer (RNFL) damage, according to a study published in the Journal of Glaucoma.

Dr Paolo Brusini et al., Department of Ophthalmology, Azienda Ospedaliero-Universitaria, Udine, Italy, conducted 320 GDx VCC tests on 84 healthy patients and 236 patients suffering from ocular hypertension or chronic open angle glaucoma. Additionally, the sensitivity and specificity of the GDx was measured in 161 patients with ocular hypertension or chronic open angle glaucoma and 34 normal patients.

The findings showed that sensitivity and the specificity of the GDx were significantly high at 88.2% and 100%, respectively. The results of clinical classification of glaucoma and the Glaucoma Staging System 2 were strongly correlated.

The GDx Staging System is a quick and effective method for classifying RNFL damage, especially for inexperienced ophthalmologists.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.